CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Telavancindrug
Likely dose
Telavancin 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01321879
NCT01321879Phase 2Completed
CompareCT.gov

Phase II, Open-Label Pilot Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

M.D. Anderson Cancer Center·interventional·Posted Mar 24, 2011·Updated Dec 27, 2019

In Brief

A Phase 2 clinical trial evaluating Telavancin for Infection and Bacteremia. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if Vibativ (telavancin) can help to control blood stream infections (BSIs). The safety of this treatment will also be studied. Objectives: Evaluate the clinical efficacy and safety of Telavancin given for treatment of gram positive bacteremia in cancer patients (including neutropenics).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection, Bacteremia
CountriesUnited States
CollaboratorsTheravance Biopharma

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 24, 2011
Enrollment StartMar 1, 2011
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 15.3 years ago

Interventions

Telavancindrug

10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.